Clinical and economic impact of rFVIIa prophylaxis in Glanzmann thrombasthenia: cohort analysis in Saudi Arabia
Ahmad Tarawah, Sami Albattat, Ayman Shahba, Mohamed Nashat, Sarah Brighton, Emily Back, Sam Bristow, George Morgan · 2026
Read Clinical and economic impact of rFVIIa prophylaxis in Glanzmann thrombasthenia: cohort analysis in Saudi Arabia by Ahmad Tarawah, Sami Albattat, Ayman Shahba, Mohamed Nashat, Sarah Brighton, Emily Back, Sam Bristow, George Morgan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13682360.txt.
Description
Glanzmann thrombasthenia is an ultra-rare inherited bleeding disorder: the platelets cannot clump, so children bleed often and land in hospital for transfusions. Eight authors studied eleven children at a Saudi specialist center who received regular preventive doses of a clotting drug, comparing each child's prophylaxis period with their own earlier years without it.
Bleeding episodes fell from a median of ten a year to four. Hospital days dropped from 96 to 24, and platelet transfusions from 63 units to 6. The drug itself is costly, but the savings on hospital care roughly cancelled it, leaving costs about neutral overall. Sensitivity checks kept the conclusion within a wide band around zero. The authors present the first evidence that prevention in this disease can pay for itself while sparing children transfusions.
Catalog record
| CREATOR | Ahmad Tarawah, Sami Albattat, Ayman Shahba, Mohamed Nashat, Sarah Brighton, Emily Back, Sam Bristow, George Morgan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |